Valley Fever Treatment
For symptomatic patients with uncomplicated pulmonary coccidioidomycosis, fluconazole 400 mg daily for 3-6 months is the recommended first-line treatment, though observation alone remains acceptable for most immunocompetent patients without risk factors. 1
Treatment Decision Algorithm
Step 1: Determine if Treatment is Needed
Observation alone is appropriate for:
- Immunocompetent patients with mild, self-limited symptoms
- No risk factors for dissemination or complications 1
Antifungal treatment is indicated for:
- Patients with diabetes, immunosuppression, or frailty due to age/comorbidities 1
- Symptoms lasting >2 months
- Severe or worsening pneumonia
- Weight loss >10%
- Night sweats persisting >3 weeks
- Infiltrates involving more than half of one lung
- Prominent hilar adenopathy
- Complement fixation antibody titers ≥1:16 1
Step 2: Select Initial Antifungal Regimen
For uncomplicated pulmonary disease:
- Fluconazole 400 mg daily (some experts use 800 mg daily) 1
- Alternative: Itraconazole 200 mg twice daily (requires monitoring for absorption and has more drug interactions) 1
- Duration: 3-6 months or longer based on clinical response 1
For severe/rapidly progressing pulmonary or disseminated disease:
- Amphotericin B intravenously until stabilized, then switch to fluconazole 1
For extrapulmonary soft tissue/bone/joint disease:
- Fluconazole 400 mg daily (or up to 800 mg daily) 1
- Alternative: Itraconazole 200 mg twice daily 1
- Duration: At least 6-12 months due to high relapse rates 1
- Exception: Severe skeletal disease or vertebral involvement with cord compromise requires initial amphotericin B 1
For coccidioidal meningitis:
- Fluconazole 400-1200 mg daily (no role for doses <400 mg in adults without renal impairment) 1
- Lifelong treatment is required 1
- If treatment failure occurs, escalate fluconazole dose first, then consider alternative azoles or intrathecal amphotericin B 1
Step 3: Special Populations
Transplant recipients (stable):
- Fluconazole 400 mg daily (adjust for renal function) 1
- Consider reducing immunosuppression if severe/rapidly progressing disease 1
Pregnant patients:
- Avoid azoles due to teratogenicity
- Use amphotericin B if treatment necessary
Critical Monitoring Parameters
During treatment, assess:
- Resolution of fever, night sweats, weight loss (typically resolve first)
- Improvement in respiratory symptoms (may be more protracted)
- Fatigue resolution (often last to improve) 1
- Complement fixation titers and chest radiographs should stabilize (complete serological resolution not required to stop treatment) 1
Discontinue treatment when:
- Signs, symptoms, and inflammatory markers have resolved
- Serologies and radiographs have stabilized
- Adequate treatment duration completed (3-6+ months for pulmonary disease) 1
Important Caveats
Observation vs. treatment controversy: No randomized trials demonstrate that azole treatment shortens illness duration or prevents complications in uncomplicated disease. One observational study showed no difference in time to 50% symptom improvement (95 vs 98 days), but 8/54 treated patients had recurrence after stopping treatment vs 0/50 untreated patients 1. This suggests treatment may be necessary for certain high-risk patients.
Itraconazole vs. fluconazole: A randomized trial showed no overall superiority, though itraconazole trended toward better efficacy at 12 months (72% vs 57% response, P=0.05) and was superior for skeletal infections 2. However, fluconazole remains preferred due to predictable absorption, fewer drug interactions, and lower cost 1.
Relapse risk: Extrapulmonary lesions can appear years after discontinuing azole treatment, requiring long-term vigilance 1. Follow complement fixation titers for at least 2 years after treatment completion.
Lumbar puncture indication: Only perform if patient has unusual/worsening/persistent headache, altered mental status, unexplained nausea/vomiting, or new focal neurologic deficits after adequate CNS imaging 1.